PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

Breast Cancer Research

Volumn 16, Issue 4, 2014, Pages

  Lehmann, Brian D ^a   Bauer, Joshua A ^a   Schafer, Johanna M ^a   Pendleton, Christopher S ^a   Tang, Luojia ^a   Johnson, Kimberly C ^a   Chen, Xi ^a   Balko, Justin M ^a   Gómez, Henry ^b   Arteaga, Carlos L ^a   Mills, Gordon B ^c   Sanders, Melinda E ^a   Pietenpol, Jennifer A ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; APITOLISIB; BICALUTAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANOLONE; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; GENE; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PIK3CA GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CLUSTER ANALYSIS; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CLUSTER ANALYSIS; DIHYDROTESTOSTERONE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919875495     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0406-x     Document Type: Article

References (25)

1. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC: Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012, 118:5463-5472.
2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
3. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767.
4. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007, 7:203.
5. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, et al: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
6. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
7. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström P-O, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65:2554-2559.
8. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT: Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009, 15:2472-2478.
9. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol 2010, 134:907-922.
10. Wolff ACA, Hammond MEHM, Schwartz JNJ, Hagerty KLK, Allred DCD, Cote RJR, Dowsett MM, Fitzgibbons PLP, Hanna WMW, Langer AA, McShane LML, Paik SS, Pegram MDM, Perez EAE, Press MFM, Rhodes AA, Sturgeon CC, Taube SES, Tubbs RR, Vance GHG, van de Vijver MM, Wheeler TMT, Hayes DFD: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Audio, Transactions of the IRE Professional Group on 2007, 25:118-143.
11. Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA: TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform 2012, 11:147-156.
12. Zhang L, Zhang L, Wei Q, Wei Q, Mao L, Mao L, Liu W, Liu W, Mills GB, Mills GB, Coombes K, Coombes K: Serial dilution curve: a new method for analysis of reverse phase protein array data. Bioinformatics 2009, 25:650-654.
13. Lin H-K, Hu Y-C, Yang L, Altuwaijri S, Chen Y-T, Kang H-Y, Chang C: Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 2003, 278:50902-50907.
14. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011, 19:575-586.
15. Kuhn E, Wu R-C, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RBS, Kuo K-T, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang T-L, Shih I-M: Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012, 104:1503-1513.
16. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N: Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci Signal 2013, 6:pl1-pl1.
17. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery 2012, 2:401-404.
18. Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL: Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS ONE 2012, 7:e34414.
19. Wang Y, Romigh T, He X, Tan MH, Orloff MS, Silverman RH, Heston WD, Eng C: Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 2011, 30:4327-4338.
20. Gucalp A, Traina TA: Triple-negative breast cancer: role of the androgen receptor. Cancer J 2010, 16:62-65.
21. Farmer PP, Bonnefoi HH, Becette VV, Tubiana-Hulin MM, Fumoleau PP, Larsimont DD, Macgrogan GG, Bergh JJ, Cameron DD, Goldstein DD, Duss SS, Nicoulaz A-LA, Brisken CC, Fiche MM, Delorenzi MM, Iggo RR: Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671.
22. Loibl S, Muller BM, Minckwitz von G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, Bois du A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C: Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011, 130:477-487.
23. Masuda H, Baggerly KA, Wang Y, Ya Z, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT: Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Canc Res 2013, 19:5533-5540.
24. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell KL, Rugo H, Nabell L, Forero-Torres A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri D, Patil S, Feigin KN, Hudis CA, Traina TA: Phase II Trial of Bicalutamide in Patients with Androgen Receptor Positive, Hormone Receptor Negative Metastatic Breast Cancer. Clin Canc Res 2013, 19:5505-5512.
25. Iwata H, Baselga J, Campone M, Arteaga CL, Cortes J, Jonat W, De Laurentiis M, Ciruelos E, Janni W, Bachelot T, Lonning PE, ORegan R, Di Tomaso E, Bharani-Dharan B, Duval V, Lau H, Germa C, Urban P, Di Leo A: Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment. J Clin Oncol 2013, 31, TPS650.